21 May 2009
How can we help patients with refractory chronic graft versus host disease – single centre experience
P Rzepecki, S OborskaAnn Transplant 2009; 14(1): 74-74 :: ID: 880472
Abstract
Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity and mortality in long-term survivors of allogeneic haematopoietic stem cell transplantation (alloHSCT). Ocular involvement as well as dermal sclerosis, joint contractures and pathological changes in oral cavity are often insurmountable to treatment. These kinds of patients require complex aggressive immunosuppressive therapy. We are still waiting for drugs against cGVHD, which will be characterised by lack of infectious complications during their administration, encouraging efficacy and rare and reversible side effects. We would like to describe eight patients who developed extensive chronic graft versus host disease with eye involvement after alloHSCT. All had ocular manifestations, which were refractory to first and second line of systemic immunosuppressive therapy. All patients responded to topical cyclosporine therapy, but clinical improvement was seen from the fifth month of starting treatment. Topical cyclosporine was well tolerated. Other four patients with sclerodermoid type of skin changes, refractory to second line of systemic immunosuppressive therapy, were treated with clofazimine. Clofazimine is a drug used to treat leprosy. Because of its anti-inflammatory effects, clofazimine is also used as a second or third line of therapy for various skin conditions including: gangrenous pyoderma, lupus erythematosus and palmoplantar pustulosis and chronic graft versus host disease. All patients that received clofazimine due to dermal sclerosis, joint contractures and oral manifestations achieved partial or complete response to treatment and were able to reduce other immunosuppressive drugs. Clofazimine was generally well tolerated.
Keywords: Bone Marrow Transplantation, Immunosuppression
In Press
06 May 2022 : Original article
Phosphatidylethanol (PEth) for Monitoring Sobriety in Liver Transplant Candidates: Preliminary Results of D...Ann Transplant In Press; DOI: 10.12659/AOT.936293
Most Viewed Current Articles
26 Jan 2022 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
29 Dec 2021 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
24 Jul 2020 : Review article
Kidney Transplantation in the Times of COVID-19 – A Literature ReviewDOI :10.12659/AOT.925755
Ann Transplant 2020; 25:e925755
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860